[Market Focus] Noel Surges on U.S. AI Medical Validation... "Outperforms Experts in Diagnosis"

Noel is showing strong performance. This appears to be influenced by news that the company has demonstrated the performance of its artificial intelligence (AI)-based malaria diagnostic solution at a U.S. academic conference.

As of 9:56 a.m. on November 12, Noel was trading at 2,745 won, up 12.04% from the previous day.

On this day, Noel announced that it had presented the clinical research results of its AI-based malaria diagnostic solution at the annual scientific meeting of the American Society of Tropical Medicine and Hygiene (ASTMH 2025), held in Toronto, Canada.

The study unveiled by Noel at ASTMH was a multicenter clinical trial conducted jointly by Noel and the Centre for Health System Strengthening (CfHSS) in Ghana, across three hospitals located in malaria-endemic regions of Ghana.

The study evaluated the diagnostic performance of miLab MAL and microscopic diagnosis compared to nPCR testing in 300 suspected malaria patients. The results showed that miLab demonstrated superior sensitivity and specificity compared to microscopic diagnosis, as well as excellent accuracy and consistency in malaria diagnosis and parasite density measurement.

According to the study results, miLab MAL achieved a sensitivity of 94.23%, specificity of 98.98%, and accuracy of 97.33% compared to nPCR testing, which was used as the reference test. These figures are higher than the performance of expert microscopic examination against nPCR, which recorded a sensitivity of 85.58%, specificity of 97.96%, and accuracy of 93.67%.

In addition, miLab MAL was able to quantitatively assess parasite density (log parasites) through automated AI-based blood image analysis, and it detected much smaller amounts of parasites compared to standard microscopic diagnosis.

Noel is also in discussions at ASTMH to form partnerships with several global pharmaceutical companies. In particular, the company is continuing discussions on participating in additional projects, based on the successful results of a phase 2 clinical trial for new drug development conducted with a European-based global pharmaceutical company.